TN2009000292A1 - Formulations for cancer treatment - Google Patents

Formulations for cancer treatment

Info

Publication number: TN2009000292A1
Authority: TN; Tunisia
Prior art keywords: formulations; cancer treatment; provides; kits; matter
Prior art date: 2007-01-16

Application number

TNP2009000292A

Other languages

English (en)

Inventor

Valeria Ossovskaya

Lingyun Li

Barry Sherman

Original Assignee

Bipar Sciences Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2007-01-16

Filing date

2009-07-07

Publication date

2010-12-31

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39350967&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=TN2009000292(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2009-07-07 Application filed by Bipar Sciences Inc filed Critical Bipar Sciences Inc

2010-12-31 Publication of TN2009000292A1 publication Critical patent/TN2009000292A1/fr

Classifications

- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
- A61K31/166—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the carbon of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/40—Cyclodextrins; Derivatives thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
- A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
- A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Pharmacology & Pharmacy (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Engineering & Computer Science (AREA)
Epidemiology (AREA)
Bioinformatics & Cheminformatics (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Nanotechnology (AREA)
Oncology (AREA)
Molecular Biology (AREA)
Biophysics (AREA)
Crystallography & Structural Chemistry (AREA)
Hematology (AREA)
Dermatology (AREA)
Dispersion Chemistry (AREA)
Biotechnology (AREA)
General Engineering & Computer Science (AREA)
Medical Informatics (AREA)
Communicable Diseases (AREA)
Diabetes (AREA)
Virology (AREA)
Oil, Petroleum & Natural Gas (AREA)
Inorganic Chemistry (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicinal Preparation (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)

TNP2009000292A 2007-01-16 2009-07-07 Formulations for cancer treatment TN2009000292A1 (en)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US88075507P	2007-01-16	2007-01-16
PCT/US2008/051214 WO2008089272A1 (fr)	2007-01-16	2008-01-16	Préparations pour le traitement du cancer

Publications (1)

Publication Number	Publication Date
TN2009000292A1 true TN2009000292A1 (en)	2010-12-31

Family

ID=39350967

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
TNP2009000292A TN2009000292A1 (en)	2007-01-16	2009-07-07	Formulations for cancer treatment

Country Status (32)

Country	Link
US (1)	US20080176946A1 (fr)
EP (2)	EP2476461A3 (fr)
JP (1)	JP2010516626A (fr)
KR (1)	KR20090113852A (fr)
CN (1)	CN101668561A (fr)
AU (1)	AU2008206294A1 (fr)
BR (1)	BRPI0806590A2 (fr)
CA (1)	CA2674600A1 (fr)
CO (1)	CO6220840A2 (fr)
CR (1)	CR10975A (fr)
CY (1)	CY1113819T1 (fr)
DK (1)	DK2121139T3 (fr)
DO (1)	DOP2009000178A (fr)
EC (1)	ECSP099577A (fr)
ES (1)	ES2395690T3 (fr)
GB (1)	GB2447796C (fr)
GT (1)	GT200900201A (fr)
HR (1)	HRP20120960T1 (fr)
IL (1)	IL199682A0 (fr)
MA (1)	MA34559B1 (fr)
MX (1)	MX2009007596A (fr)
NZ (1)	NZ579098A (fr)
PL (1)	PL2121139T3 (fr)
PT (1)	PT2121139E (fr)
RS (1)	RS52633B (fr)
RU (2)	RU2481830C2 (fr)
SG (1)	SG178714A1 (fr)
SI (1)	SI2121139T1 (fr)
SV (1)	SV2009003335A (fr)
TN (1)	TN2009000292A1 (fr)
UA (1)	UA100852C2 (fr)
WO (1)	WO2008089272A1 (fr)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US7961081B2 (en) *	2003-05-22	2011-06-14	John Tomlienovic	Anti-theft system and method
BRPI0611814A2 (pt) *	2005-06-10	2008-12-09	Bipar Sciences Inc	moduladores parp e tratamento de cÂnceres
ZA200800907B (en)	2005-07-18	2010-04-28	Bipar Sciences Inc	Treatment of cancer
US20080262062A1 (en) *	2006-11-20	2008-10-23	Bipar Sciences, Inc.	Method of treating diseases with parp inhibitors
EP2038654A4 (fr) *	2006-06-12	2010-08-11	Bipar Sciences Inc	Procédé permettant de traiter des maladies avec des inhibiteurs de parp
US20100160442A1 (en) *	2006-07-18	2010-06-24	Ossovskaya Valeria S	Formulations for cancer treatment
US7538252B2 (en) *	2006-09-05	2009-05-26	Bipar Sciences, Inc.	Drug design for tubulin inhibitors, compositions, and methods of treatment thereof
JP2010502730A (ja)	2006-09-05	2010-01-28	バイパーサイエンシズ，インコーポレイティド	癌の治療法
JP2010502731A (ja)	2006-09-05	2010-01-28	バイパーサイエンシズ，インコーポレイティド	Ｐａｒｐ阻害剤による脂肪酸合成の阻害、及びその治療方法
EP2211854A4 (fr) *	2007-10-19	2011-01-12	Bipar Sciences Inc	Procédés et compositions pour le traitement du cancer au moyen d'inhibiteurs de parp de type benzopyrone
CN101917982B (zh)	2007-11-12	2013-03-20	彼帕科学公司	使用4-碘-3-硝基苯甲酰胺与抗肿瘤剂组合治疗乳腺癌
AU2009212401A1 (en) *	2008-02-04	2009-08-13	Bipar Sciences, Inc.	Methods of diagnosing and treating PARP-mediated diseases
US8026271B2 (en) *	2008-07-11	2011-09-27	National Health Research Institutes	Formulations of indol-3-yl-2-oxoacetamide compounds
WO2010036226A1 (fr) *	2008-09-26	2010-04-01	George Nelson	Méthode de traitement de la polyarthrite rhumatoïde, des tremblements/de la maladie de parkinson et de la sclérose en plaques
MX2011003277A (es) *	2008-10-14	2012-09-21	Salubrious Pharmaceuticals LLC	Proceso para el tratamiento de la artritis reumatoide, temblores/enfermedad de parkinson, esclerosis multiple y cancer de tipo no viral.
EP2709618A4 (fr) *	2011-05-10	2014-11-05	UNIVERSITé LAVAL	Procédés pour le traitement et le diagnostic de l'hypertension artérielle pulmonaire
EP2925299B1 (fr) *	2012-11-30	2018-06-06	Novartis AG	Nouvelle composition pharmaceutique
WO2017192618A1 (fr)	2016-05-02	2017-11-09	Symbios Technologies, Inc.	Agents chimiothérapeutiques aqueux activés par plasma électrochimique
US11433074B2 (en)	2017-06-22	2022-09-06	Triact Therapeutics, Inc.	Methods of treating glioblastoma
US11730725B2 (en)	2017-09-26	2023-08-22	Tesaro, Inc.	Niraparib formulations
US11628144B2 (en)	2017-09-29	2023-04-18	Triact Therapeutics, Inc.	Iniparib formulations and uses thereof
WO2020246737A1 (fr) *	2019-06-04	2020-12-10	사회복지법인 삼성생명공익재단	Composition pour le traitement du cancer de la prostate résistant à la castration, comprenant des quassinoïdes
CZ309587B6 (cs) *	2021-01-22	2023-05-03	Oncora S.R.O.	Mikroemulzní prekoncentrát s obsahem kladribinu a způsob jeho přípravy
GB2611315B (en) *	2021-09-29	2024-01-03	Siemens Healthcare Gmbh	Method of operating a magnetic resonance scanner
WO2023239919A1 (fr) *	2022-06-10	2023-12-14	Dana-Farber Cancer Institute, Inc.	Un déséquilibre allélique de l'accessibilité de la chromatine dans le cancer identifie des variants de risque causal et leurs mécanismes

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JPH0348655A (ja) *	1989-07-14	1991-03-01	Shionogi & Co Ltd	プロスタグランジンｄ↓２類の安定化
US5633282A (en) *	1990-05-25	1997-05-27	British Technology Group Limited	Inhibition of viral infection
US5637618A (en) *	1990-06-01	1997-06-10	Bioresearch, Inc.	Specific eatable taste modifiers
US5232735A (en) *	1990-06-01	1993-08-03	Bioresearch, Inc.	Ingestibles containing substantially tasteless sweetness inhibitors as bitter taste reducers or substantially tasteless bitter inhibitors as sweet taste reducers
US5631038A (en) *	1990-06-01	1997-05-20	Bioresearch, Inc.	Specific eatable taste modifiers
US5484951A (en) *	1990-10-19	1996-01-16	Octamer, Incorporated	5-iodo-6-amino-6-nitroso-1,2-benzopyrones useful as cytostatic and antiviral agents
US5753674A (en) *	1991-10-22	1998-05-19	Octamer, Inc.	Adenosine diphosphoribose polymerase binding nitroso aromatic compounds useful as retroviral inactivating agents, anti-retroviral agents, anti-retroviral agents and anti-tumor agents
US5877185A (en) *	1991-10-22	1999-03-02	Octamer, Inc.	Synergistic compositions useful as anti-tumor agents
US5464871A (en)	1993-05-12	1995-11-07	Octamer, Inc.	Aromatic nitro and nitroso compounds and their metabolites useful as anti-viral and anti-tumor agents
US5482975A (en) *	1991-10-22	1996-01-09	Octamer, Inc.	Adenosine diphosphoribose polymerase binding nitroso aromatic compounds useful as retroviral inactivating agents, anti-retroviral agents and anti-tumor agents
US5516941A (en) *	1991-10-22	1996-05-14	Octamer, Inc.	Specific inactivators of "retroviral" (asymmetric) zinc fingers
GB9200247D0 (en) *	1992-01-07	1992-02-26	Erba Carlo Spa	Pharmaceutical compositions containing polymer derivative-bound anthracycline glycosides and a method for their preparation
US5558855A (en)	1993-01-25	1996-09-24	Sonus Pharmaceuticals	Phase shift colloids as ultrasound contrast agents
US6008250A (en) *	1993-05-26	1999-12-28	Bioresearch, Inc.	Specific eatable taste modifiers
US6015792A (en) *	1993-05-26	2000-01-18	Bioresearch, Inc.	Specific eatable taste modifiers
US5589483A (en) *	1994-12-21	1996-12-31	Geron Corporation	Isoquinoline poly (ADP-ribose) polymerase inhibitors to treat skin diseases associated with cellular senescence
AU5780696A (en) *	1995-06-02	1996-12-18	Takeda Chemical Industries Ltd.	Stabilized composition comprising an antiulcerative benzimid azole
US5837729A (en) *	1996-04-26	1998-11-17	Metatron, Inc.	Methods for treating and preventing HIV infection using acetaminophen and derivatives thereof
EP0973727B8 (fr) *	1997-04-10	2006-01-18	Isotechnika International, Inc.	Derives d'iode actives utilises dans le traitement du cancer et du sida
US5908861A (en) *	1997-05-13	1999-06-01	Octamer, Inc.	Methods for treating inflammation and inflammatory disease using pADPRT inhibitors
US6696426B2 (en) *	2000-08-22	2004-02-24	Pharmacia Corporation	Preservative free ophthalmic oxazolidinone antibiotic drug delivery systems
EP1348432A4 (fr) *	2001-01-04	2005-08-10	Daiichi Seiyaku Co	Preparation pharmaceutique contenant de la cyclodextrine
US20050113283A1 (en) *	2002-01-18	2005-05-26	David Solow-Cordero	Methods of treating conditions associated with an EDG-4 receptor
JP2003321364A (ja) *	2002-05-07	2003-11-11	Eisai Co Ltd	シクロデキストリンにより可溶化及び安定化された抗腫瘍剤含有組成物
AU2004206844A1 (en) *	2003-01-14	2004-08-05	Teva Pharmaceutical Industries, Ltd.	Parenteral formulations of a peptide for the treatment of systemic lupus erythematosus
WO2005023765A1 (fr) *	2003-09-11	2005-03-17	Pharmacia & Upjohn Company Llc	Methode de catalyse de reactions d'amidation au moyen de co2
BRPI0611814A2 (pt) *	2005-06-10	2008-12-09	Bipar Sciences Inc	moduladores parp e tratamento de cÂnceres
ZA200800907B (en) *	2005-07-18	2010-04-28	Bipar Sciences Inc	Treatment of cancer
EP2038654A4 (fr) *	2006-06-12	2010-08-11	Bipar Sciences Inc	Procédé permettant de traiter des maladies avec des inhibiteurs de parp
AU2007292302A1 (en) *	2006-09-05	2008-03-13	Bipar Sciences, Inc.	Methods for designing PARP inhibitors and uses thereof
US7538252B2 (en) *	2006-09-05	2009-05-26	Bipar Sciences, Inc.	Drug design for tubulin inhibitors, compositions, and methods of treatment thereof
JP2010502731A (ja) *	2006-09-05	2010-01-28	バイパーサイエンシズ，インコーポレイティド	Ｐａｒｐ阻害剤による脂肪酸合成の阻害、及びその治療方法
JP2010502730A (ja) *	2006-09-05	2010-01-28	バイパーサイエンシズ，インコーポレイティド	癌の治療法

2008
- 2008-01-16 SG SG2012003109A patent/SG178714A1/en unknown
- 2008-01-16 DK DK08727771.1T patent/DK2121139T3/da active
- 2008-01-16 HR HRP20120960AT patent/HRP20120960T1/hr unknown
- 2008-01-16 SI SI200830855T patent/SI2121139T1/sl unknown
- 2008-01-16 ES ES08727771T patent/ES2395690T3/es active Active
- 2008-01-16 AU AU2008206294A patent/AU2008206294A1/en not_active Withdrawn
- 2008-01-16 MX MX2009007596A patent/MX2009007596A/es active IP Right Grant
- 2008-01-16 US US12/015,403 patent/US20080176946A1/en not_active Abandoned
- 2008-01-16 RS RS20120544A patent/RS52633B/sr unknown
- 2008-01-16 CN CN200880008617A patent/CN101668561A/zh active Pending
- 2008-01-16 KR KR1020097017060A patent/KR20090113852A/ko not_active Withdrawn
- 2008-01-16 WO PCT/US2008/051214 patent/WO2008089272A1/fr not_active Ceased
- 2008-01-16 PL PL08727771T patent/PL2121139T3/pl unknown
- 2008-01-16 EP EP11192725A patent/EP2476461A3/fr not_active Withdrawn
- 2008-01-16 RU RU2009130599/15A patent/RU2481830C2/ru not_active IP Right Cessation
- 2008-01-16 PT PT87277711T patent/PT2121139E/pt unknown
- 2008-01-16 GB GB0807263A patent/GB2447796C/en not_active Withdrawn - After Issue
- 2008-01-16 UA UAA200908564A patent/UA100852C2/ru unknown
- 2008-01-16 CA CA002674600A patent/CA2674600A1/fr not_active Withdrawn
- 2008-01-16 NZ NZ579098A patent/NZ579098A/en not_active IP Right Cessation
- 2008-01-16 EP EP08727771A patent/EP2121139B1/fr active Active
- 2008-01-16 JP JP2009545734A patent/JP2010516626A/ja not_active Withdrawn
- 2008-01-16 BR BRPI0806590-0A patent/BRPI0806590A2/pt not_active Application Discontinuation
- 2008-01-16 MA MA32171A patent/MA34559B1/fr unknown
2009
- 2009-07-02 IL IL199682A patent/IL199682A0/en unknown
- 2009-07-07 TN TNP2009000292A patent/TN2009000292A1/fr unknown
- 2009-07-14 DO DO2009000178A patent/DOP2009000178A/es unknown
- 2009-07-15 GT GT200900201A patent/GT200900201A/es unknown
- 2009-07-15 SV SV2009003335A patent/SV2009003335A/es unknown
- 2009-08-13 EC EC2009009577A patent/ECSP099577A/es unknown
- 2009-08-14 CO CO09085583A patent/CO6220840A2/es not_active Application Discontinuation
- 2009-08-14 CR CR10975A patent/CR10975A/es unknown
2012
- 2012-12-03 RU RU2012151571/15A patent/RU2012151571A/ru unknown
2013
- 2013-01-09 CY CY20131100023T patent/CY1113819T1/el unknown

Also Published As

Publication number	Publication date
MA34559B1 (fr)	2013-10-02
RU2481830C2 (ru)	2013-05-20
NZ579098A (en)	2012-07-27
KR20090113852A (ko)	2009-11-02
EP2476461A3 (fr)	2012-10-24
US20080176946A1 (en)	2008-07-24
GT200900201A (es)	2011-06-23
HK1121697A1 (zh)	2009-04-30
EP2121139A1 (fr)	2009-11-25
SV2009003335A (es)	2010-02-05
BRPI0806590A2 (pt)	2013-07-23
EP2476461A2 (fr)	2012-07-18
PT2121139E (pt)	2012-12-12
WO2008089272A1 (fr)	2008-07-24
IL199682A0 (en)	2010-04-15
RU2009130599A (ru)	2011-02-27
CN101668561A (zh)	2010-03-10
RU2012151571A (ru)	2014-06-10
GB2447796A (en)	2008-09-24
HRP20120960T1 (hr)	2012-12-31
ECSP099577A (es)	2009-10-30
EP2121139B1 (fr)	2012-10-10
GB0807263D0 (en)	2008-05-28
RS52633B (sr)	2013-06-28
GB2447796B (en)	2009-03-04
DK2121139T3 (da)	2013-01-14
PL2121139T3 (pl)	2013-03-29
CY1113819T1 (el)	2016-07-27
CR10975A (es)	2009-10-15
SG178714A1 (en)	2012-03-29
ES2395690T3 (es)	2013-02-14
UA100852C2 (ru)	2013-02-11
SI2121139T1 (sl)	2013-01-31
MX2009007596A (es)	2009-08-13
JP2010516626A (ja)	2010-05-20
CO6220840A2 (es)	2010-11-19
AU2008206294A1 (en)	2008-07-24
DOP2009000178A (es)	2009-10-31
HK1137158A1 (en)	2010-07-23
GB2447796C (en)	2009-11-12
CA2674600A1 (fr)	2008-07-24

Publication	Publication Date	Title
TN2009000292A1 (en)	2010-12-31	Formulations for cancer treatment
MX361467B (es)	2018-12-06	Compuestos de isoindolina para uso en el tratamiento de cancer.
SG164368A1 (en)	2010-09-29	Treatment of cancer
MX2011010390A (es)	2011-12-14	Conjugados, particulas, composiciones de agentes polimericos y metodos relacionados de uso.
IL260127B (en)	2022-04-01	mek inhibitors and methods of using them
SG10201811480WA (en)	2019-01-30	Therapeutic compounds and compositions
UA95310C2 (ru)	2011-07-25	Композиция, содержащая ингибитор chk1 и циклодекстрин, для лечения рака
WO2006107451A3 (fr)	2006-11-30	Derives d'honokiol pour traiter les maladies proliferantes
EA201690265A3 (ru)	2016-10-31	Фармацевтические композиции, содержащие замещенные ациланилиды
WO2010118063A3 (fr)	2011-01-27	Compositions thérapeutiques et procédés d'utilisation associés
EA201290131A1 (ru)	2012-08-30	Производные пурина или деазапурина для применения при лечении вирусных инфекций и других заболеваний
MX2009008347A (es)	2009-10-19	Oxabicicloheptanos y oxabicicloheptenos, su preparacion y uso.
TNSN07322A1 (en)	2008-12-31	Pyrimidine derivatives for treatment of hyperproliferative disorders
TNSN08370A1 (en)	2009-12-29	Tetrahydropyridothienopyrimidine compounds and methods of use thereof
MX2010006203A (es)	2010-06-25	Derivados de pirazol y uso de los mismos como inhibidores de cinasas dependientes de ciclina.
MX2007011545A (es)	2008-03-11	Combinaciones para el tratamiento de cancer que comprenden el anticuerpo anti-egfr e inhibidores de vegfr.
PH12013502370A1 (en)	2014-08-27	Multiheteroaryl compounds as inhibitors of h-pgds and their use for treating prostaglandin d2 mediated diseases
MX2008015775A (es)	2009-04-17	Compuestos y composiciones para tratamiento de cancer.
GEP20135818B (en)	2013-05-10	Nitrogenated derivatives of pancratistatin
EP2124554A4 (fr)	2009-12-30	Compositions et procédés pour le traitement du cancer
WO2007146375A3 (fr)	2008-04-03	Composés de pyrimido-dione-quinoléine hautement solubles et procédés de traitement du cancer
TN2010000232A1 (en)	2011-11-11	Formulations for cancer treatment
MY148355A (en)	2013-03-29	Crystal form of epothilone b and use in pharmaceutical compositions
WO2010129670A3 (fr)	2011-03-17	Procédé de modulation de l'angiogenèse à l'aide de fibromoduline
TNSN08062A1 (en)	2009-07-14	Microparticle compositions of the topoisomerase i inhibitor 7-tert-butoxyiminomethylcamptothecin